Back to Search Start Over

Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma

Authors :
Morgane Creoff
Morgan Michalet
Olivier Riou
Florence Castan
Boris Guiu
Eric Assenat
Jessica Prunaretty
Georges-Philippe Pageaux
Marie Cantaloube
Marc Ychou
N. Aillères
David Azria
Karl Bordeau
Pascal Fenoglietto
Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM)
CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Institut du Cancer de Montpellier (ICM)
Oncodoc
Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi]
Hôpital Saint Eloi (CHRU Montpellier)
Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM)
Salvy-Córdoba, Nathalie
Source :
Cancers, Vol 13, Iss 4853, p 4853 (2021), Cancers; Volume 13; Issue 19; Pages: 4853, Cancers, Cancers, MDPI, 2021, 13 (19), pp.4853. ⟨10.3390/cancers13194853⟩
Publication Year :
2021
Publisher :
MDPI AG, 2021.

Abstract

Simple Summary Although the use of stereotactic body radiation therapy (SBRT) in the management of hepatocellular carcinoma (HCC) remains unclear, it is a therapeutic option often considered in patients not eligible to or recurring after other local therapies. Liver SBRT can be delivered using a wide range of techniques and linear accelerators. We report the first evaluation for HCC of SBRT using volumetric modulated arc therapy (VMAT) and real-time adaptive tumor gating, which is a mainly completely non-invasive procedure (no fiducial markers for 65.2% of the patients). Our study showed that this SBRT technique has very favorable outcomes with optimal local control and a low toxicity rate. Abstract Liver SBRT is a therapeutic option for the treatment of HCC in patients not eligible for other local therapies. We retrospectively report the outcomes of a cohort of consecutive patients treated with SBRT for HCC at the Montpellier Cancer Institute. Between March 2013 and December 2018, 66 patients were treated with image-guided liver SBRT using VMAT and real-time adaptive tumor gating in our institute. The main endpoints considered in this study were local control, disease-free survival, overall survival, and toxicity. The median follow-up was 16.8 months. About 66.7% had prior liver treatment. Most patients received 50 Gy in five fractions of 10 Gy. No patient had local recurrence. Overall survival and disease-free survival were, respectively, 83.9% and 46.7% at one year. In multivariate analysis, the diameter of the lesions was a significant prognostic factor associated with disease-free survival (HR = 2.57 (1.19–5.53) p = 0.02). Regarding overall survival, the volume of PTV was associated with lower overall survival (HR = 2.84 (1.14–7.08) p = 0.025). No grade 3 toxicity was observed. One patient developed a grade 4 gastric ulcer, despite the dose constraints being respected. Image-guided liver SBRT with VMAT is an effective and safe treatment in patients with inoperable HCC, even in heavily pre-treated patients. Further prospective evaluation will help to clarify the role of SBRT in the management of HCC patients.

Details

Language :
English
ISSN :
20726694
Volume :
13
Issue :
4853
Database :
OpenAIRE
Journal :
Cancers
Accession number :
edsair.doi.dedup.....64e2474a2054cd5f84a1e4d7c6fbf598